ToxSci Advance Access published online on August 9, 2007
Toxicological Sciences, doi:10.1093/toxsci/kfm206
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Published by Oxford University Press 2007.
The PPAR
-humanized Mouse: a Model to Investigate Species Differences in Liver Toxicity Mediated by PPAR
Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892
Correspondence: Frank J. Gonzalez, Building 37, Room 3106, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892. Phone: (301) 496-9067. Fax: (301) 496-8419. E-mail: fjgonz{at}helix.nih.gov
Received July 27, 2007; revision received July 31, 2007; accepted August 1, 2007
| Abstract |
|---|
To determine the impact of the species difference between rodents and humans in response to peroxisome proliferators mediated by PPAR
, PPAR
humanized transgenic mice were generated using a PAC genomic clone bred onto a Ppar
-null mouse background, designated hPPAR
PAC. In hPPAR
PAC mice, the human PPAR
gene is expressed in tissues with high fatty acid catabolism and induced upon fasting, similar to mouse PPAR
in wild-type mice. Upon treatment with the peroxisome proliferator fenofibrate, hPPAR
PAC mice exhibited responses similar to wild-type mice, including peroxisome proliferation, lowering of serum triglycerides and induction of PPAR
target genes encoding enzymes involved in fatty acid metabolism in liver, kidney and heart, suggesting that human PPAR
functions in the same manner as mouse PPAR
in regulating fatty acid metabolism and lowering serum triglycerides. However, in contrast to wild-type mice, treatment of hPPAR
PAC mice with fenofibrate did not cause significant hepatomegaly and hepatocyte proliferation, thus indicating that the mechanisms by which PPAR
affects lipid metabolism are distinct from the hepatocyte proliferation response, the latter of which is only induced by mouse PPAR
. In addition, a differential regulation of several genes, including the oncogenic let-7C miRNA by peroxisome proliferators was observed between wild-type and hPPAR
PAC mice that may contribute to the inherent difference between mouse and human PPAR
in activation of hepatocellular proliferation. The hPPAR
PAC mouse model provides an in vivo platform to investigate the species difference mediated by PPAR
and an ideal model for human risk assessment peroxisome proliferators exposure.
Key Words: Humanized; PAC; PPAR
; hepatomegaly; peroxisome proliferators.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
D. C. Wolf, T. Moore, B. D. Abbott, M. B. Rosen, K. P. Das, R. D. Zehr, A. B. Lindstrom, M. J. Strynar, and C. Lau Comparative Hepatic Effects of Perfluorooctanoic Acid and WY 14,643 in PPAR-{alpha} Knockout and Wild-type Mice Toxicol Pathol, June 1, 2008; 36(4): 632 - 639. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Lambert, N. Ancellin, F. Charlton, D. Comas, J. Pilot, A. Keech, S. Patel, D. R. Sullivan, J. S. Cohn, K.-A. Rye, et al. Plasma PCSK9 Concentrations Correlate with LDL and Total Cholesterol in Diabetic Patients and Are Decreased by Fenofibrate Treatment Clin. Chem., June 1, 2008; 54(6): 1038 - 1045. [Abstract] [Full Text] [PDF] |
||||

